Comparison between the EUCAST Procedure and the Etest for Determination of the Susceptibility of Candida Species Isolates to Micafungin
暂无分享,去创建一个
[1] M. Castanheira,et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] C. Clancy,et al. The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata , 2012, Antimicrobial Agents and Chemotherapy.
[3] M. Arendrup,et al. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[4] M. Pfaller,et al. Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012 , 2012, Journal of Clinical Microbiology.
[5] M. Cuenca‐Estrella,et al. Recurrent Episodes of Candidemia Due to Candida glabrata with a Mutation in Hot Spot 1 of the FKS2 Gene Developed after Prolonged Therapy with Caspofungin , 2012, Antimicrobial Agents and Chemotherapy.
[6] M. Arendrup,et al. Echinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden , 2011, Journal of Clinical Microbiology.
[7] M. Arendrup,et al. Disseminated Candidiasis Caused by Candida albicans with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin , 2011, Antimicrobial Agents and Chemotherapy.
[8] C. Bonnal,et al. Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[9] M. Castanheira,et al. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species , 2010, Journal of Clinical Microbiology.
[10] M. Arendrup,et al. Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media , 2009, Antimicrobial Agents and Chemotherapy.
[11] J. Cleary,et al. Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint , 2009, Antimicrobial Agents and Chemotherapy.
[12] D. Perlin,et al. Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints , 2008, Antimicrobial Agents and Chemotherapy.
[13] F. Dromer,et al. Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing , 2008, Antimicrobial Agents and Chemotherapy.
[14] Subcommittee on Antifungal Susceptibility Testing. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[15] J. Donnelly,et al. Correlation of the MIC and Dose/MIC Ratio of Fluconazole to the Therapeutic Response of Patients with Mucosal Candidiasis and Candidemia , 2007, Antimicrobial Agents and Chemotherapy.
[16] D. Perlin. Resistance to echinocandin-class antifungal drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[17] T. Peláez,et al. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. , 2007, Diagnostic microbiology and infectious disease.
[18] T. Peláez,et al. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. , 2006, Diagnostic microbiology and infectious disease.
[19] M. Cuenca‐Estrella,et al. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing Proposed Standard and the E-Test with the NCCLS Broth Microdilution Method for Voriconazole and Caspofungin Susceptibility Testing of Yeast Species , 2002, Journal of Clinical Microbiology.
[20] A. Espinel-Ingroff. Clinical utility of in vitro antifungal susceptibility testing. , 2000, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
[21] J. Martínez-Suárez,et al. Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. , 1995, The Journal of antimicrobial chemotherapy.
[22] Thomas J. White,et al. PCR protocols: a guide to methods and applications. , 1990 .
[23] T. White. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics , 1990 .